H

Hualan Biological Bacterin Inc
SZSE:301207

Watchlist Manager
Hualan Biological Bacterin Inc
SZSE:301207
Watchlist
Price: 19.12 CNY -5.3% Market Closed
Market Cap: 11.5B CNY
Have any thoughts about
Hualan Biological Bacterin Inc?
Write Note

Hualan Biological Bacterin Inc
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hualan Biological Bacterin Inc
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
H
Hualan Biological Bacterin Inc
SZSE:301207
Accounts Receivables
ÂĄ2B
CAGR 3-Years
9%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Accounts Receivables
ÂĄ2.5B
CAGR 3-Years
86%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Accounts Receivables
ÂĄ3B
CAGR 3-Years
63%
CAGR 5-Years
74%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Accounts Receivables
ÂĄ949.9m
CAGR 3-Years
26%
CAGR 5-Years
3%
CAGR 10-Years
25%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Accounts Receivables
ÂĄ25.5B
CAGR 3-Years
43%
CAGR 5-Years
44%
CAGR 10-Years
51%
Imeik Technology Development Co Ltd
SZSE:300896
Accounts Receivables
ÂĄ206.1m
CAGR 3-Years
91%
CAGR 5-Years
87%
CAGR 10-Years
N/A
No Stocks Found

Hualan Biological Bacterin Inc
Glance View

Market Cap
11.5B CNY
Industry
Biotechnology

Hualan Biological Bacterin Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Xinxiang, Henan and currently employs 917 full-time employees. The company went IPO on 2022-02-18. Hualan Biological Bacterin Inc is a China-based company specializing in the research, development, production and sales of human vaccines. The firm's listed products mainly include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A H1N1 split vaccine, recombinant hepatitis B vaccine and others. The firm's products that have been approved for clinical trials or have passed clinical registration and are pending for marketing mainly include human rabies vaccines, adsorbed tetanus vaccines, H7N9 influenza whole virus inactivated vaccines and others. The firm's products in the preclinical research stage include inactivated new coronavirus vaccine, freeze-dried nasal spray recombinant new coronavirus live attenuated vaccine and others.

Intrinsic Value
30.08 CNY
Undervaluation 36%
Intrinsic Value
Price
H

See Also

What is Hualan Biological Bacterin Inc's Accounts Receivables?
Accounts Receivables
2B CNY

Based on the financial report for Dec 31, 2023, Hualan Biological Bacterin Inc's Accounts Receivables amounts to 2B CNY.

What is Hualan Biological Bacterin Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
30%

Over the last year, the Accounts Receivables growth was 11%. The average annual Accounts Receivables growth rates for Hualan Biological Bacterin Inc have been 9% over the past three years , 30% over the past five years .

Back to Top